NASDAQ:NBIX - Neurocrine Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $126.53
  • Forecasted Upside: 13.91 %
  • Number of Analysts: 19
  • Breakdown:
  • 0 Sell Ratings
  • 8 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
$111.08
▲ +2.3 (2.11%)
1 month | 3 months | 12 months
Get New Neurocrine Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NBIX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NBIX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$126.53
▲ +13.91% Upside Potential
This price target is based on 19 analysts offering 12 month price targets for Neurocrine Biosciences in the last 3 months. The average price target is $126.53, with a high forecast of $149.00 and a low forecast of $90.00. The average price target represents a 13.91% upside from the last price of $111.08.
Buy
The current consensus among 19 contributing investment analysts is to buy stock in Neurocrine Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 13 buy ratings
  • 7 hold ratings
  • 0 sell ratings
7/30/2019
  • 0 strong buy ratings
  • 12 buy ratings
  • 7 hold ratings
  • 0 sell ratings
10/28/2019
  • 0 strong buy ratings
  • 10 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/26/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 0 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 8 hold ratings
  • 0 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 8 hold ratings
  • 0 sell ratings
12/21/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 8 hold ratings
  • 0 sell ratings
1/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 8 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/29/2020Cantor FitzgeraldLower Price TargetOverweight$168.00 ➝ $121.00N/A
i
12/16/2020Morgan StanleyLower Price TargetOverweight$133.00 ➝ $121.00Medium
i
12/7/2020WedbushLower Price TargetOutperform$129.00 ➝ $121.00High
i
Rating by L. Chico at Wedbush
11/12/2020Canaccord GenuityLower Price TargetBuy$145.00 ➝ $122.00Low
i
11/10/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellLower Price Target$149.00 ➝ $138.00Low
i
11/10/2020OppenheimerLower Price Target$150.00 ➝ $145.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
11/10/2020Smith Barney CitigroupLower Price Target$149.00 ➝ $138.00Low
i
11/10/2020William BlairReiterated RatingOutperformLow
i
11/10/2020WedbushLower Price TargetOutperform$147.00 ➝ $129.00Medium
i
Rating by L. Chico at Wedbush
11/10/2020Credit Suisse GroupLower Price TargetNeutral$105.00 ➝ $90.00High
i
11/10/2020MizuhoLower Price TargetNeutral$132.00 ➝ $117.00High
i
11/10/2020SVB LeerinkLower Price TargetMarket Perform$120.00 ➝ $100.00High
i
10/29/2020OppenheimerLower Price TargetOutperform$155.00 ➝ $150.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
9/30/2020BenchmarkInitiated CoverageHoldHigh
i
8/4/2020Credit Suisse GroupLower Price TargetNeutral$135.00 ➝ $126.00High
i
8/4/2020Canaccord GenuityBoost Price TargetBuy$134.00 ➝ $145.00High
i
8/4/2020Morgan StanleyLower Price TargetOverweight$149.00 ➝ $146.00High
i
8/4/2020HC WainwrightBoost Price TargetBuy$131.00 ➝ $140.00High
i
Rating by Andrew Fein at HC Wainwright
8/4/2020Cantor FitzgeraldBoost Price TargetOverweight$144.00 ➝ $161.00High
i
8/4/2020MizuhoBoost Price TargetNeutral$127.00 ➝ $132.00High
i
8/4/2020SVB LeerinkBoost Price TargetMarket Perform$105.00 ➝ $120.00High
i
8/4/2020Piper SandlerBoost Price TargetOverweight$141.00 ➝ $145.00High
i
Rating by David Amsellem at Piper Sandler
8/4/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$136.00High
i
7/23/2020MizuhoBoost Price TargetNeutral$105.00 ➝ $127.00Medium
i
Rating by Vamil Divan at Mizuho
7/20/2020Credit Suisse GroupBoost Price TargetNeutral$101.00 ➝ $135.00Medium
i
7/17/2020OppenheimerBoost Price TargetOutperform$142.00 ➝ $152.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
7/15/2020Morgan StanleyBoost Price TargetOverweight$120.00 ➝ $149.00Low
i
6/29/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$135.00High
i
6/26/2020CitigroupBoost Price TargetBuy$124.00 ➝ $149.00High
i
Rating by Neena Bitritto-Garg at Citigroup Inc.
6/18/2020JPMorgan Chase & Co.Boost Price TargetIn-Line ➝ Overweight$122.00 ➝ $134.00Medium
i
6/18/2020Royal Bank of CanadaBoost Price TargetOutperform$116.00 ➝ $135.00Low
i
6/17/2020HC WainwrightReiterated RatingBuy$125.00 ➝ $131.00Low
i
Rating by A. Fein at HC Wainwright
6/16/2020Needham & Company LLCInitiated CoverageHoldLow
i
Rating by Alan Carr at Needham & Company LLC
6/16/2020OppenheimerInitiated CoverageBuy$142.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
6/10/2020Canaccord GenuityBoost Price TargetBuy$123.00 ➝ $134.00Low
i
6/8/2020WedbushInitiated CoverageOutperform$147.00Low
i
Rating by L. Chico at Wedbush
6/1/2020Piper SandlerReiterated RatingBuy$126.00Low
i
Rating by David Amsellem at Piper Sandler
5/7/2020Canaccord GenuityBoost Price TargetBuy$122.00 ➝ $123.00High
i
5/7/2020BarclaysBoost Price TargetEqual Weight$105.00 ➝ $108.00High
i
5/7/2020MizuhoBoost Price TargetNeutral$103.00 ➝ $105.00High
i
Rating by Vamil Divan at Mizuho
5/7/2020Morgan StanleyLower Price TargetBuy$121.00 ➝ $120.00High
i
5/7/2020HC WainwrightReiterated RatingBuy$125.00High
i
Rating by A. Fein at HC Wainwright
5/7/2020Needham & Company LLCReiterated RatingHoldHigh
i
Rating by Alan Carr at Needham & Company LLC
4/30/2020William BlairReiterated RatingBuyHigh
i
Rating by M. Minter at William Blair
4/27/2020Needham & Company LLCReiterated RatingHoldMedium
i
4/13/2020OppenheimerLower Price TargetOutperform$132.00 ➝ $130.00Low
i
4/8/2020Piper SandlerLower Price Target$147.00 ➝ $125.00Medium
i
4/8/2020Needham & Company LLCReiterated RatingHold ➝ NeutralMedium
i
4/8/2020Royal Bank of CanadaReiterated RatingBuy$104.00Medium
i
3/5/2020CitigroupInitiated CoverageBuy$124.00Medium
i
2/27/2020BarclaysInitiated CoverageEqual Weight$105.00High
i
2/24/2020William BlairInitiated CoverageOutperform$116.00High
i
Rating by M. Minter at William Blair
2/14/2020Stifel NicolausReiterated RatingBuy$127.00N/A
i
Rating by Paul Matteis at Stifel Nicolaus
2/5/2020MizuhoInitiated CoverageNeutral$107.00Low
i
2/5/2020HC WainwrightReiterated RatingBuy$102.00 ➝ $125.00Medium
i
1/20/2020Royal Bank of CanadaReiterated RatingBuy$125.00Low
i
Rating by Brian Abrahams at Royal Bank of Canada
1/17/2020Morgan StanleyBoost Price TargetOverweight$120.00 ➝ $121.00Medium
i
1/13/2020OppenheimerBoost Price TargetOutperform$115.00 ➝ $132.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
12/17/2019Morgan StanleyBoost Price TargetOverweight$110.00 ➝ $120.00Medium
i
12/13/2019Credit Suisse GroupDowngradeOutperform ➝ Neutral$110.00Low
i
12/12/2019Piper Jaffray CompaniesReiterated RatingOverweight$116.00 ➝ $153.00Medium
i
11/5/2019Piper Jaffray CompaniesBoost Price Target$111.00 ➝ $116.00Low
i
9/6/2019Royal Bank of CanadaSet Price TargetBuy$118.00Medium
i
Rating by Brian Abrahams at Royal Bank of Canada
8/7/2019Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$118.00Low
i
7/31/2019Needham & Company LLCReiterated RatingHoldMedium
i
7/30/2019Credit Suisse GroupBoost Price TargetOutperform$95.00 ➝ $110.00High
i
7/30/2019Piper Jaffray CompaniesBoost Price TargetOverweight$103.00 ➝ $111.00High
i
7/16/2019CIBCInitiated CoverageOutperform ➝ Outperform$100.00Low
i
7/16/2019OppenheimerInitiated CoverageOutperform$100.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
7/15/2019Stifel NicolausSet Price TargetBuy$113.00Low
i
Rating by Paul Matteis at Stifel Nicolaus
6/4/2019GuggenheimInitiated CoverageNeutral ➝ Neutral$88.00Medium
i
5/20/2019Credit Suisse GroupInitiated CoverageOutperform$95.00Medium
i
4/22/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$100.00 ➝ $106.00High
i
4/11/2019Evercore ISIInitiated CoverageOutperformLow
i
3/29/2019BarclaysReiterated RatingBuy$110.00High
i
3/13/2019OppenheimerBoost Price TargetOutperform$105.00 ➝ $110.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
2/6/2019Bank of AmericaLower Price TargetBuy$124.00 ➝ $117.00Medium
i
2/6/2019Cantor FitzgeraldReiterated RatingOverweightHigh
i
Rating by Charles Duncan at Cantor Fitzgerald
1/30/2019HC WainwrightReiterated RatingBuyMedium
i
1/29/2019Cantor FitzgeraldReiterated RatingBuy$121.00Medium
i
Rating by Charles Duncan at Cantor Fitzgerald
1/29/2019OppenheimerSet Price TargetBuy$105.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
1/24/2019Needham & Company LLCDowngradeBuy ➝ HoldLow
i
Rating by Alan Carr at Needham & Company LLC
1/23/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$97.00 ➝ $100.00Medium
i
1/15/2019HC WainwrightReiterated RatingBuy$102.00High
i
1/6/2019OppenheimerSet Price TargetBuy$105.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
12/13/2018OppenheimerLower Price TargetOutperform$140.00 ➝ $105.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
12/13/2018JPMorgan Chase & Co.Lower Price TargetOverweight$127.00 ➝ $97.00Low
i
12/13/2018Robert W. BairdLower Price TargetOutperform$131.00 ➝ $96.00Medium
i
12/13/2018SVB LeerinkLower Price TargetMarket Perform$110.00 ➝ $84.00Medium
i
Rating by M. Goodman at SVB Leerink LLC
12/13/2018Canaccord GenuityLower Price TargetBuy$111.00 ➝ $100.00Medium
i
12/13/2018HC WainwrightReiterated RatingBuy$162.00Medium
i
12/13/2018The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$103.00Medium
i
Rating by Paul Choi at The Goldman Sachs Group, Inc.
12/13/2018BarclaysReiterated RatingBuy$95.00Medium
i
12/12/2018Stifel NicolausLower Price TargetBuy$115.00 ➝ $17.07High
i
12/12/2018Cantor FitzgeraldReiterated RatingBuy$121.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
12/12/2018Needham & Company LLCSet Price TargetBuy$104.00High
i
Rating by Alan Carr at Needham & Company LLC
12/11/2018OppenheimerSet Price TargetBuy$140.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
12/5/2018Cantor FitzgeraldSet Price TargetBuy$150.00Low
i
Rating by Charles Duncan at Cantor Fitzgerald
11/21/2018Canaccord GenuityInitiated CoverageBuy ➝ Buy$111.00Low
i
11/12/2018SVB LeerinkInitiated CoverageMarket Perform$110.00High
i
Rating by M. Goodman at SVB Leerink LLC
11/6/2018Morgan StanleyLower Price TargetOverweight ➝ Buy$145.00 ➝ $135.00Low
i
Rating by Jeffrey Hung at Morgan Stanley
11/6/2018Piper Jaffray CompaniesSet Price TargetBuy$111.00High
i
Rating by David Amsellem at Piper Jaffray Companies
11/5/2018Cantor FitzgeraldSet Price TargetBuy$150.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
11/5/2018OppenheimerSet Price TargetBuy$140.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
10/5/2018Piper Jaffray CompaniesSet Price TargetBuy$115.00Low
i
Rating by David Amsellem at Piper Jaffray Companies
9/20/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$137.00 ➝ $142.00Low
i
9/20/2018Cantor FitzgeraldSet Price TargetBuy$150.00Low
i
Rating by Charles Duncan at Cantor Fitzgerald
9/14/2018Cantor FitzgeraldInitiated CoverageBuy$150.00Low
i
Rating by Charles Duncan at Cantor Fitzgerald
9/12/2018OppenheimerSet Price TargetBuy$140.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
9/10/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$145.00Medium
i
9/4/2018ICAPLower Price TargetOutperform$140.00 ➝ $128.00Medium
i
9/4/2018OppenheimerSet Price TargetBuy$140.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
8/22/2018Cantor FitzgeraldInitiated CoverageOverweight$150.00Low
i
Rating by C. Duncan at Cantor Fitzgerald
8/7/2018Stifel NicolausInitiated CoverageBuy$137.00Low
i
8/1/2018Needham & Company LLCSet Price TargetBuy$125.00Low
i
Rating by Alan Carr at Needham & Company LLC
8/1/2018HC WainwrightReiterated RatingBuy$162.00High
i
8/1/2018BarclaysBoost Price TargetOverweight ➝ Overweight$100.00 ➝ $135.00High
i
Rating by Geoff Meacham at Barclays PLC
7/31/2018OppenheimerSet Price TargetBuy$128.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
7/30/2018Jefferies Financial GroupBoost Price TargetBuy$124.00High
i
7/25/2018Robert W. BairdReiterated RatingOutperform ➝ Outperform$100.00 ➝ $122.00High
i
7/16/2018JPMorgan Chase & Co.Boost Price TargetOverweight$127.00Medium
i
6/8/2018BarclaysSet Price TargetBuy$100.00Low
i
Rating by Geoff Meacham at Barclays PLC
5/14/2018OppenheimerSet Price TargetBuy$120.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
5/7/2018CowenReiterated RatingBuy$100.00Low
i
5/1/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$101.00 ➝ $102.00High
i
5/1/2018Deutsche Bank AktiengesellschaftSet Price TargetBuy ➝ Buy$97.00 ➝ $99.00High
i
Rating by Andrew Peters at Deutsche Bank Aktiengesellschaft
5/1/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$100.00 ➝ $103.00High
i
5/1/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$84.00 ➝ $100.00High
i
4/10/2018OppenheimerSet Price TargetBuy$110.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
3/21/2018OppenheimerReiterated RatingBuyLow
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
3/14/2018Piper Jaffray CompaniesReiterated RatingOverweight$113.00Medium
i
Rating by Charles Duncan at Piper Jaffray Companies
3/13/2018OppenheimerSet Price TargetBuy$110.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
2/22/2018OppenheimerSet Price TargetBuy$110.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
2/22/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$95.00 ➝ $110.00Low
i
2/20/2018SVB LeerinkBoost Price TargetOutperform$90.00 ➝ $96.00Medium
i
2/14/2018Deutsche Bank AktiengesellschaftBoost Price TargetBuy$97.00Medium
i
2/14/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$79.00 ➝ $100.00High
i
2/14/2018BarclaysReiterated RatingOverweight$100.00High
i
2/14/2018OppenheimerSet Price TargetBuy$95.00 ➝ $100.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
1/16/2018Needham & Company LLCBoost Price TargetBuy$95.00High
i
1/15/2018OppenheimerSet Price TargetBuy$85.00 ➝ $95.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
1/5/2018Jefferies Financial GroupBoost Price TargetBuy$105.00Medium
i
12/12/2017OppenheimerSet Price TargetBuy$85.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
11/14/2017OppenheimerSet Price TargetBuy$85.00N/A
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
11/3/2017Robert W. BairdReiterated RatingBuy$84.00N/A
i
11/2/2017Needham & Company LLCReiterated RatingBuy$86.00N/A
i
11/2/2017BarclaysBoost Price TargetOverweight$75.00 ➝ $85.00N/A
i
11/2/2017OppenheimerBoost Price TargetOutperform$70.00 ➝ $85.00N/A
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
11/2/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$79.00N/A
i
11/2/2017BMO Capital MarketsBoost Price TargetPositive ➝ Outperform$83.00 ➝ $109.00N/A
i
11/2/2017SVB LeerinkReiterated RatingOutperform$72.00 ➝ $83.00N/A
i
11/2/2017CitigroupReiterated RatingBuy$79.00N/A
i
10/25/2017Piper Jaffray CompaniesReiterated RatingBuy$76.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
10/10/2017SVB LeerinkReiterated RatingOutperform$67.00 ➝ $72.00N/A
i
10/5/2017BMO Capital MarketsReiterated RatingOutperform$84.00N/A
i
10/3/2017Jefferies Financial GroupReiterated RatingBuy$66.00 ➝ $69.00Low
i
9/21/2017Robert W. BairdReiterated RatingOutperform$66.00High
i
9/17/2017Needham & Company LLCReiterated RatingBuy$58.00Low
i
9/7/2017OppenheimerReiterated RatingBuy$70.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
8/24/2017Piper Jaffray CompaniesSet Price TargetBuy$68.00Medium
i
Rating by Charles Duncan at Piper Jaffray Companies
8/9/2017CowenReiterated RatingOutperform$60.00 ➝ $65.00Medium
i
8/4/2017BMO Capital MarketsBoost Price TargetOutperform$75.00 ➝ $84.00Low
i
7/5/2017OppenheimerReiterated RatingOutperform$70.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
5/30/2017Jefferies Financial GroupReiterated RatingBuy$66.00Low
i
5/25/2017BMO Capital MarketsReiterated RatingOutperform$75.00Low
i
5/25/2017SVB LeerinkLower Price TargetOutperform$68.00 ➝ $66.00Low
i
5/24/2017OppenheimerSet Price TargetBuy$70.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
5/24/2017Piper Jaffray CompaniesSet Price TargetBuy$68.00Medium
i
Rating by Charles Duncan at Piper Jaffray Companies
5/24/2017JPMorgan Chase & Co.Set Price TargetBuy$57.00Medium
i
Rating by Anupam Rama at JPMorgan Chase & Co.
5/24/2017Needham & Company LLCReiterated RatingBuy$62.00 ➝ $58.00Low
i
5/22/2017Jefferies Financial GroupReiterated RatingBuy$67.00Medium
i
5/15/2017Bank of AmericaReiterated RatingBuy$70.00Medium
i
5/9/2017Jefferies Financial GroupReiterated RatingBuy$67.00Medium
i
5/5/2017Bank of AmericaInitiated CoverageBuy ➝ Buy$70.00Low
i
5/2/2017BarclaysBoost Price TargetOverweight$60.00 ➝ $70.00Low
i
5/1/2017Jefferies Financial GroupBoost Price TargetBuy$65.00 ➝ $67.00Medium
i
4/17/2017Needham & Company LLCReiterated RatingBuy$62.00Low
i
4/17/2017BMO Capital MarketsReiterated RatingOutperform$72.00Low
i
4/17/2017Piper Jaffray CompaniesReiterated RatingOverweight$80.00Low
i
Rating by Charles Duncan at Piper Jaffray Companies
4/14/2017Robert W. BairdReiterated RatingOutperform$66.00N/A
i
Rating by Brian Skorney at Robert W. Baird
4/12/2017JPMorgan Chase & Co.Set Price TargetBuy$60.00Medium
i
Rating by Anupam Rama at JPMorgan Chase & Co.
4/12/2017Jefferies Financial GroupBoost Price TargetBuy$59.00 ➝ $65.00High
i
4/8/2017OppenheimerSet Price TargetBuy$60.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
4/4/2017Jefferies Financial GroupReiterated RatingBuy$58.00High
i
3/27/2017BarclaysReiterated RatingOverweight$60.00Low
i
3/17/2017Needham & Company LLCReiterated RatingBuy$62.00Low
i
3/7/2017Cantor FitzgeraldReiterated RatingOverweight$80.00N/A
i
3/7/2017Piper Jaffray CompaniesReiterated RatingOutperform$80.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
2/16/2017Needham & Company LLCReiterated RatingBuy$62.00N/A
i
2/16/2017HC WainwrightBoost Price TargetPositive$80.00 ➝ $100.00N/A
i
2/15/2017CowenReiterated RatingBuyN/A
i
Rating by Phil Nadeau at Cowen Inc
2/15/2017Robert W. BairdReiterated RatingOutperform$66.00N/A
i
Rating by Brian Skorney at Robert W. Baird
2/14/2017OppenheimerSet Price TargetBuy$60.00N/A
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
2/10/2017OppenheimerReiterated RatingOutperform$55.00 ➝ $55.00N/A
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
2/10/2017Needham & Company LLCReiterated RatingBuy$62.00N/A
i
2/10/2017ICAPReiterated RatingOutperform$55.00N/A
i
2/10/2017Piper Jaffray CompaniesReiterated RatingOverweight$96.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
2/9/2017SVB LeerinkReiterated RatingOutperform$65.00N/A
i
Rating by P. Matteis at SVB Leerink LLC
1/30/2017Piper Jaffray CompaniesReiterated RatingOverweight$96.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
1/27/2017CIBCUpgradeMarket Perform ➝ OutperformN/A
i
1/27/2017OppenheimerUpgradeMarket Perform ➝ Outperform$55.00N/A
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
1/19/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$65.00 ➝ $62.00N/A
i
1/19/2017BMO Capital MarketsReiterated RatingOutperform$72.00N/A
i
1/18/2017CowenSet Price TargetBuy$65.00N/A
i
Rating by Phil Nadeau at Cowen Inc
1/18/2017HC WainwrightReiterated RatingBuyN/A
i
1/18/2017Needham & Company LLCReiterated RatingBuy$62.00N/A
i
1/18/2017Jefferies Financial GroupLower Price TargetBuy$61.00 ➝ $56.00N/A
i
1/18/2017Piper Jaffray CompaniesReiterated RatingBuy$96.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
1/18/2017Robert W. BairdReiterated RatingOutperform$66.00N/A
i
Rating by Brian Skorney at Robert W. Baird
1/15/2017OppenheimerReiterated RatingMarket Perform$55.00N/A
i
1/9/2017Needham & Company LLCReiterated RatingBuy$62.00N/A
i
1/8/2017Robert W. BairdReiterated RatingBuy$66.00N/A
i
Rating by Brian Skorney at Robert W. Baird
1/8/2017Piper Jaffray CompaniesReiterated RatingOverweight$96.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
12/23/2016SVB LeerinkReiterated RatingOutperform$70.00N/A
i
Rating by P. Matteis at SVB Leerink LLC
12/7/2016Piper Jaffray CompaniesReiterated RatingOverweight$96.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
11/22/2016OppenheimerInitiated CoverageMarket Perform$55.00N/A
i
11/22/2016CitigroupInitiated CoverageMarket Perform$55.00N/A
i
11/8/2016Jefferies Financial GroupReiterated RatingSell$61.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
11/3/2016BMO Capital MarketsReiterated RatingBuy$72.00N/A
i
11/3/2016BarclaysReiterated RatingBuy$60.00N/A
i
11/3/2016Piper Jaffray CompaniesReiterated RatingOverweight$96.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
11/3/2016Deutsche Bank AktiengesellschaftInitiated CoverageBuy$65.00N/A
i
10/27/2016BMO Capital MarketsReiterated RatingOutperform$66.00 ➝ $72.00N/A
i
10/18/2016Piper Jaffray CompaniesReiterated RatingOverweight$96.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
10/18/2016Needham & Company LLCInitiated CoverageBuy$62.00N/A
i
10/13/2016BMO Capital MarketsReiterated RatingOutperform$66.00N/A
i
10/12/2016SVB LeerinkReiterated RatingOutperform$70.00N/A
i
Rating by P. Matteis at SVB Leerink LLC
10/11/2016Piper Jaffray CompaniesSet Price TargetBuy$96.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
10/4/2016SVB LeerinkInitiated CoverageOutperform$70.00N/A
i
Rating by P. Matteis at SVB Leerink LLC
9/23/2016BMO Capital MarketsReiterated RatingOutperform$66.00N/A
i
9/23/2016Jefferies Financial GroupReiterated RatingBuy$61.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
9/22/2016Piper Jaffray CompaniesReiterated RatingOverweight$96.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
8/30/2016Robert W. BairdReiterated RatingOutperform$66.00N/A
i
Rating by Brian Skorney at Robert W. Baird
8/5/2016CowenReiterated RatingBuy$65.00N/A
i
Rating by Phil Nadeau at Cowen Inc
8/5/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by Andrew Fein at HC Wainwright
6/29/2016HC WainwrightInitiated CoverageBuy$80.00N/A
i
6/8/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
6/7/2016Piper Jaffray CompaniesReiterated RatingOverweight$96.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
6/1/2016SVB LeerinkReiterated RatingOutperform$63.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
5/25/2016Jefferies Financial GroupReiterated RatingBuy$61.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
5/19/2016Jefferies Financial GroupReiterated RatingBuy$58.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
5/16/2016Piper Jaffray CompaniesReiterated RatingOverweight$96.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
5/8/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
5/8/2016Robert W. BairdReiterated RatingBuyN/A
i
Rating by Brian Skorney at Robert W. Baird
5/4/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
Rating by Anupam Rama at JPMorgan Chase & Co.
4/14/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
4/12/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
Rating by Anupam Rama at JPMorgan Chase & Co.
4/12/2016BMO Capital MarketsReiterated RatingOutperform$57.00N/A
i
4/6/2016BMO Capital MarketsInitiated CoverageOutperformN/A
i
4/4/2016Piper Jaffray CompaniesReiterated RatingOverweight$96.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
3/28/2016Jefferies Financial GroupReiterated RatingBuy$60.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
2/12/2016CowenReiterated RatingBuy$65.00N/A
i
Rating by Phil Nadeau at Cowen Inc
2/11/2016Piper Jaffray CompaniesReiterated RatingOverweight$96.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
2/9/2016JPMorgan Chase & Co.Reiterated RatingBuy$70.00 ➝ $63.00N/A
i
Rating by Anupam Rama at JPMorgan Chase & Co.
1/22/2016SVB LeerinkReiterated RatingBuy$71.00 ➝ $76.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
(Data available from 1/20/2016 forward)
Neurocrine Biosciences logo
Neurocrine Biosciences, Inc., a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) for the treatment of tardive dyskinesia; and ORILISSA, a gonadotropin-releasing hormone antagonist for use in the treatment of endometriosis. Its product candidates in clinical development include elagolix that has completed Phase III clinical trial for uterine fibroids; opicapone, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBIb-1817, an AADC gene replacement therapy, which is in Phase II clinical trial for the treatment of Parkinson's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients with SCN8A-DEE, as well as other indications, such as adult focal epilepsy; ACT-709478, an orally active and brain penetrating T-type calcium channel blocker for use in certain forms of generalized epilepsy; and VMAT2 inhibitor for the treatment of various neurology and/or psychiatry disorders. Neurocrine Biosciences, Inc. has collaborations and agreements with AbbVie Inc.; BIAL Â- Portela & Ca, S.A.; Voyager Therapeutics, Inc.; Xenon Pharmaceuticals Inc.; Mitsubishi Tanabe Pharma Corporation; Idorsia Pharmaceuticals Ltd; and Takeda Pharmaceutical Company Limited. The company was founded in 1992 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $111.08
$108.01
$111.75

50 Day Range

MA: $99.79
$90.21
$112.32

52 Week Range

Now: $111.08
$72.14
$136.26

Volume

680,667 shs

Average Volume

1,007,070 shs

Market Capitalization

$10.38 billion

P/E Ratio

119.44

Dividend Yield

N/A

Beta

1.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Neurocrine Biosciences?

The following Wall Street sell-side analysts have issued research reports on Neurocrine Biosciences in the last twelve months: Barclays PLC, Benchmark Co., Canaccord Genuity, Cantor Fitzgerald, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Credit Suisse Group AG, HC Wainwright, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, Smith Barney Citigroup, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, Wedbush, William Blair, and Zacks Investment Research.

What is the current price target for Neurocrine Biosciences?

19 Wall Street analysts have set twelve-month price targets for Neurocrine Biosciences in the last year. Their average twelve-month price target is $126.53, suggesting a possible upside of 16.3%. Citigroup Inc. has the highest price target set, predicting NBIX will reach $149.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $90.00 for Neurocrine Biosciences in the next year.

What is the current consensus analyst rating for Neurocrine Biosciences?

Neurocrine Biosciences currently has 8 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NBIX will outperform the market and that investors should add to their positions of Neurocrine Biosciences.

What other companies compete with Neurocrine Biosciences?

How do I contact Neurocrine Biosciences' investor relations team?

Neurocrine Biosciences' physical mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company's listed phone number is 858-617-7600 and its investor relations email address is ir@neurocrine.com. The official website for Neurocrine Biosciences is www.neurocrine.com.